Abstract
Background Pyrotinib, a pan-HER tyrosine kinase inhibitor, demonstrates efficacy in the treatment of HER2-positive breast cancer. However, the frequent occurrence of treatment-emergent diarrhea necessitating discontinuation, impacts patient outcomes.
Methods In this multicenter, open-label, phase II PHAEDRA study enrolling early stage HER2-positive patients for postoperative treatment with nab-paclitaxel and pyrotinib, 120 patients were included in a sub-study and randomly divided into two groups to receive 21 days and 42 days of loperamide for primary prophylaxis of diarrhea, followed by as-needed usage. The primary outcome was the incidence of grade ≥3 diarrhea.
Results Fifty-eight patients in the 21-day group and 59 patients in the 42-day group received at least one dose of pyrotinib. With a median follow-up of 12.1 months, all patients experienced diarrhea of any grade, with grade ≥3 events in 39.7% of the 21-day group and 42.4% of the 42-day group (relative risk: 0.94; 95% confidence interval: 0.61-1.45). The most common treatment-emergent adverse events, other than diarrhea, were hypoesthesia, vomiting, nausea, and rash, mostly grade 1-2, except for one patient with a grade ≥3 decreased neutrophil count in each group.
Conclusion No significant differences were observed between 21-day and 42-day loperamide durations in preventing grade ≥3 diarrhea. Considering the economic cost and patient compliance, 21-day loperamide prophylaxis might represent a more pragmatic and appropriate approach for clinical application.
Trial registration: ClinicalTrials.gov, NCT04659499
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04659499
Funding Statement
The study drugs pyrotinib and nab-paclitaxel were provided by Jiangsu Hengrui Pharmaceuticals Co., Ltd. This study was funded by the National High-Level Hospital Clinical Research Funding (No. 2022-PUMCH-B-038 and No. 2022-PUMCH-C-066) and TSC China Allicace (#LAM001-202205).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional ethics committee at the Peking Union Medical College Hospital (approval number: HS-2617) with informed consent obtained from all patients in accordance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure2 revised; Figure3 revised; Figure4 revised. Affiliations in the manuscript revised; Statistical analysis updated.
Data Availability
The raw clinical data were protected and not available owing to data privacy laws. The de-identified datasets supporting the findings of this study are available for academic purposes on request from the corresponding author, Qiang Sun (sunqiangpumch{at}sina.com), for five years, with the approval of the Institutional Ethical Committees.
